The activating protein-1 (AP-1) transcription factor transduces growth signals through signal transduction pathways to the nucleus, leading to the expression of genes involved in growth and malignant transformation in many cell types. We have previously shown that overexpression of a dominant negative form of the cJun proto-oncogene, a cJun dominant negative mutant (Tam67), blocks AP-1 transcriptional activity, induces a G 1 cell cycle block and inhibits breast cancer cell growth in vitro and in vivo. We found that AP-1 blockade by Tam67 in MCF-7 breast cancer cells downregulates cyclin D1 transcriptional activity by at least two mechanisms: by suppressing transcription at the known AP-1 binding site (À934/À928) and by suppressing growth factor-induced expression through suppressing E2F activation at the E2F-responsive site (À726/À719). AP-1 blockade also led to reduced expression of E2F1 and E2F2, but not E2F4, at the mRNA and protein levels. Chromatin immunoprecipitation and supershift assays demonstrated that AP-1 blockade caused decreased binding of E2F1 protein to the E2F site in the cyclin D1 promoter. We also found that Tam67 suppressed the expression of the E2F1 dimerizing partner, DP1 and E2F-upregulated cell cycle genes (cyclins E, A, B and D3) and enhanced the expression of E2F-downregulated cell cycle genes (cyclins G 2 and I). Reduced expression of other E2F-regulated genes was also seen with AP-1 blockade and E2F suppression. Thus, the AP-1 factor regulates the expression of cyclin D and E2F (the latter in turn regulates E2F-downstream genes), leading to cell cycle progression and breast cancer cell proliferation.
Introduction
The activating protein-1 (AP-1) family of transcription factors consists of multiple Jun (cJun, JunB and JunD) and Fos (cFos, FosB, Fra-1 and Fra-2) members (Angel and Karin, 1991) . The Jun members either homodimerize with Jun itself or heterodimerize with different Fos members, whereas Fos members heterodimerize only with Jun members. Thus, Jun is the predominant partner to form AP-1 complexes such as Jun:Jun or Jun:Fos dimers. The AP-1 complex converges multiple growth signals at the transcriptional level, making it a critical connecting node for many signal transduction pathways. We and other investigators have shown that AP-1 regulates cellular proliferation, differentiation, apoptosis, oncogene-induced transformation and cancer cell invasion (McDonnell et al., 1990; Szabo et al., 1991; Brown et al., 1993) . Proliferation of breast cells requires signals from growth factors such as estrogen, epidermal growth factor (EGF), transforming growth factor a (TGFa), heregulin and insulin-like growth factors (IGFs), and these factors activate AP-1 signaling. Therefore, blockade of AP-1 complex may arrest multiple growth signals important for breast cell proliferation and transformation.
We have previously shown that AP-1 blockade induced by expression of a specific AP-1 inhibitor (a cJun dominant-negative mutant, Tam67) suppressed the growth of breast cancer cells induced by many growth factors such as estrogen, EGF, heregulin and IGF-1 . We also demonstrated that AP-1 blockade by Tam67 arrested cell cycle at the G 1 phase . In addition, G 1 cyclins were downregulated at the mRNA and protein levels when breast cancer cells were synchronized at the G 2 /M phase and released from synchronization by serum stimulation . However, the explicit mechanism by which AP-1 blockade regulates the cell cycle remains unclear.
Potential consensus AP-1 binding sites or AP-1-like binding sites have been found in the promoter of the cyclin D1 gene (Herber et al., 1994) . In the present study, we measured cyclin D1 expression at the mRNA and protein levels in MCF-7 cells synchronized at G 0 /G 1 phases, and determined that the consensus AP-1 binding site is responsible for maintaining basal cyclin D1 promoter activity. We further demonstrated that an E2F site present in the cyclin D1 promoter was required for the Tam67-induced suppression of cyclin D1 expression. We then demonstrated that AP-1 and E2F factors bind to AP-1 and E2F binding sites in the cyclin D1 promoter. We also determined that E2F1 and E2F2, and their dimerizing partner DP1 were downregulated by Tam67, as were many E2F downstream genes. Thus, the AP-1 transcription factor regulates breast cancer cell growth via multiple mechanisms, including regulation of cyclin D1, E2F factors and their target genes. These findings support that the AP-1 transcription factor is a critical regulator of breast cell proliferation, making this factor a potential target for the treatment and prevention of breast cancer.
Results
AP-1 blockade by Tam67 downregulates cyclin D1 at the mRNA and protein levels in MCF-7 cells We have previously shown that AP-1 blockade by Tam67 reduced cyclins D1, D2, D3 and cyclin E at the mRNA and protein level in MCF-7 cells synchronized at G 2 /M phase . Here, we examined the effect of Tam67 on cyclin D1 expression in MCF-7 cells synchronized at G 0 /G 1 phase and released from synchronization by serum stimulation. We confirmed that Tam67 expression suppressed cyclin D1 mRNA by more than 50% in these cells (P ¼ 0.0004) (Figures 1a  and b) . Tam67 reduced the expression of cyclin D1 mRNA, while control cells still show a cyclic pattern (Figure 1b ). Tam67 also reduced the protein level of cyclin D1 (Figures 1c and d) . Note that the maintained cyclic pattern of cyclin D1 protein expression still occurs suggesting that other mechanisms such as proteolysis still contribute to the degradation of cyclin D1.
Tam67 suppresses cyclin D1 promoter activity Since Tam67 suppressed cyclin D1 mRNA expression, we investigated whether the transcription factors that bind at the AP-1 site regulate cyclin D1 transcription. Potential binding sites for AP-1, E2F, nuclear factor-kB (NF-kB) and Sp1 factors were found in the promoter region of À2963 to þ 361 of the cyclin D1 promoter (Herber et al., 1994) . To determine the cis-elements responsible for the Tam67-induced inhibition, we examined the promoter activity for cyclin D1 gene in the presence and absence of Tam67 expression. We found that deletion of the AP-1 site at -934/À928 reduced cyclin D1 promoter activity (in the absence of Tam67) by approximately 40% (Figure 2a) . Deletion of the NF-kB site at À840/À831 did not alter the promoter activity significantly. However, induction of Tam67 still suppressed the promoter activity in constructs lacking the AP-1 and NF-kB sites. Only when the E2F site was deleted did we observe loss of Tam67-induced suppression of promoter activity. This result suggests that AP-1 transcription factors bind to the AP-1 site to regulate basal cyclin D1 expression and that Tam67 suppresses cyclin D1 expression in part by affecting the proteins that bind the E2F site in the cyclin D1 promoter.
We next mutated the E2F sites at À726/À719 and À139/À131 (Figure 2b) . Mutation of the E2F site at À139/À131 resulted in a slight decrease in promoter activity, while the Tam67-induced suppression remained the same. Mutation of the E2F site at À726/À719 caused loss of Tam67-induced suppression of promoter activity ( Figure 2b ). As shown in Figure 2c , the fragment containing the E2F site at À726/À719 was ligated back to the shortest construct used that does not have the E2F site at À726/À719, and the resulting promoter construct restored the repression by Tam67. These results confirm the importance of the E2F site at À726/À719 in the AP-1 regulation of cyclin D1. Our studies demonstrate that AP-1 regulates cyclin D1 expression by at least two mechanisms: activation of basal cyclin D1 promoter activity via the AP-1 site and further by increasing E2F activity. Thus both the AP-1 and E2F factors play important roles in regulating cyclin D1 expression in breast cancer cells.
Interaction of the AP-1 inhibitor, Tam67, with the promoter elements of cyclin D1 gene We next performed chromatin immunoprecipitation (ChIP) assays to demonstrate in vivo interaction between Tam67 and the AP-1 or E2F site within the cyclin D1 promoter. Using cJun and cFos antibodies as positive controls, we found that cJun and cFos bound to the DNA fragments containing the AP-1 sites of either a positive control gene (collagenase/MMP-1) or the cyclin D1 gene (Figure 3a) . As shown using an anti-flag antibody in these ChIP experiments, flag-tagged Tam67 was found to bind the AP-1 sites of the control MMP-1 and cyclin D1 promoters in doxycycline-untreated, thus Tam67-induced MCF-7 cells, but not in control cells (Figure 3a ). This suggests that Tam67 complex does bind to the AP-1 site in the cyclin D1 promoter, supporting the conclusion from Figure 2 that AP-1 maintains basal cyclin D1 promoter function. The ChIP assays also show that the E2F1 protein, but not cJun or cFos, bound to the E2F site in the cyclin D1 promoter.
To further verify the in vivo binding results, we performed in vitro electrophoretic mobility shift assay (EMSA) and supershift assays to determine direct or indirect interaction of Tam67 and E2F1 proteins to respective binding sites. We found that Tam67 is capable of binding the AP-1 site in the cyclin D1 promoter (Figure 3b , lane 7), consistent with our results of reporter assays showing suppression of the basal cyclin D1 promoter activity (Figure 2 ). Tam67 did not bind the E2F element of the cyclin D1 promoter at À726/À719 (Figure 3b , lanes 13 and 14). As expected, E2F1 protein does bind the E2F site ( Figure 3b , lanes 15 and 16). We also observed reduced binding of E2F1 protein to the E2F site in Tam67-expressing cells (Figure 3b, lanes 10 and 14) . This result suggests that Tam67 either affects E2F expression or affects E2F DNA binding activity. Tam67 did not bind the NF-kB and Sp1 sites ( Figure 3c , lanes 6 and 7, and lanes 13 and 14, respectively). Taken together, the ChIP and supershift data suggest that the AP-1 inhibitor, Tam67, AP-1 blockade downregulates cyclins and E2F1 Q Shen et al suppresses cyclin D1 expression by directly attenuating cyclin D1 promoter activity through blockade at the AP-1 site, and indirectly reducing binding of E2F1 to the E2F site in the cyclin D1 promoter.
AP-1 blockade suppresses E2F1, E2F2 and DP1, but not E2F4 expression
We next determined whether reduced binding of E2F1 to the E2F site was due to decreased E2F1 protein expression in AP-1 blocked MCF-7 cells. We found that Tam67 expression leads to reduced E2F1 and E2F2, but not E2F4 mRNA levels as assessed by RNase protection assays (RPAs) (P ¼ 0.01 for E2F1 and E2F2) . The E2F dimerizing partner, DP1, was also suppressed at the mRNA level (Figures 4a and e) (P ¼ 0.0004), while DP2 was not (data not shown). Protein levels for E2F1, E2F2 and DP1 were reduced upon AP-1 blockade, while the expression of E2F4 was upregulated (Figures 4f and i) . Thus, AP-1 blockade by Tam67 differentially regulates the expression of E2F1, E2F2, E2F4 and their dimerizing partner DP1, resulting 
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Q Shen et al in modulated expression of E2F-dependent genes (including cyclin D1).
E2F target genes are regulated upon AP-1 blockade
We next examined the expression of E2F-downstream genes. Cyclin E is a direct target gene of E2F1 (DeGregori et al., 1995; Botz et al., 1996) . We found that Tam67 suppressed cyclin E mRNA at all time points examined, showing a 30-60% suppression (P ¼ 0.0005) (Figures 5a and b) . Protein levels for cyclin E were reduced as well (Figures 5c and d) . These results suggest that the reduction of E2F1 activity induced by Tam67 leads to reduced expression of cyclin E. Figure 2 Promoter activity of cyclin D1 gene. MCF-7 Tet-Off Tam67 cells were cultured in the presence/absence of doxycycline (Dox) for 5 days and co-transfected with the deletion constructs of cyclin D1 promoter and dual luciferase/renilla pRL-TK vector. Luciferase activity was measured and normalized with the renilla activity. (a) Deletion of the activating protein-1 (AP-1) site at À934/À928 partially reduced promoter activity, while deletion of the E2F site at À726/À719 resulted in the loss of Tam67-induced inhibition of promoter activity. (b) Promoter activity after mutation of the E2F sites in the cyclin D1 promoter. (c) Addition of the fragment containing the E2F site at À726/À719 back to the D1D-543pXP2 vector. Rescue of the E2F site at À726/À719 restored Tam67-induced repression of the cyclin D1 promoter activity. 
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We also discovered that the expression of other cyclins regulated by E2F was also altered by expression of Tam67. Cyclin A and cyclin B (both are E2F-upregulated genes) were suppressed upon Tam67-induced AP-1 blockade (Figure 6a ), while cyclins G 2 and I, both E2F-downregulated genes, were upregulated in the presence of AP-1 blockade (Figure 6b ). In addition, we identified that cyclins C, G 1 and H were not regulated in the presence of Tam67 (Figure 6c) . Results from these studies support an important role of E2F1 in mediating the effects of AP-1 blockade induced by Tam67.
We next examined the expression of other downstream target genes of E2F. The b-myb, PCNA and cathepsin D genes are directly regulated by E2F1 (DeGregori et al., 1995; Lavia and Jansen-Durr, 1999) . We found reduced expression of these genes in the AP-1-blocked MCF-7 cells (Figure 7a ), while Bcl-2 and RARg genes were upregulated in the presence of AP-1 blockade, as shown by quantitative reverse-transcriptase-PCR (QRT-PCR) (Figure 7b) . As a control, the TOB1 gene did not show significant changes in mRNA levels (Figure 7c) . Thus, we have demonstrated that AP-1 blockade by Tam67 causes downregulation of cyclins, in addition to genes involved in DNA replication and repair (for example, PCNA). In addition, the E2F downstream target genes were also regulated upon AP-1 blockade. 
These results support a role for AP-1 in regulating cell cycle at several checkpoints.
Discussion
In these studies, we investigated the molecular mechanisms by which the AP-1 inhibitor, Tam67, suppresses breast cancer cell growth. We have shown that AP-1 blockade suppresses cyclin D1 at the mRNA and protein levels, and have defined the mechanisms of this downregulation (shown schematically in Figure 8 ). First, AP-1 blockade suppresses basal cyclin D1 activity which is controlled by the consensus AP-1 binding site within the cyclin D1 promoter. Second, suppression of cyclin D1 expression also occurs via an indirect mechanism by downregulation of the E2F1 and E2F2 transcriptional factors, leading to reduced binding of E2F protein to the E2F binding site within the cyclin D1 promoter. Third, AP-1 blockade suppresses the expression of E2F dimerizing partner, DP1, thus reducing the availability of the E2F/DP1 complex and modulating the expression of E2F1-targeted genes. Finally, 
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suppression of the expression of E2F1-targeted genes further enhances the growth-suppressive effect of Tam67 (Figure 8 ).
The role of cyclin D1 in cancer cell growth has been well documented and reviewed (Donnellan and Chetty, 1998) . Signals from growth factors and mitogens eventually activate AP-1, which in turn activates cyclin D1. Cyclin D1 regulation by AP-1 has also been reported in other breast cancer cells, such as T47D and SKBR3 cells (Shah et al., 2002; Bu et al., 2005) , and in silica-induced transformed embryonic lung fibroblasts (Shen et al., 2006a) . However, these previous studies have not fully described the mechanism by which AP-1 regulates cyclin D1. Our results herein demonstrate several mechanisms that may coexist to allow modulation of cell cycle regulators such as cyclin D1 and cyclin E. Thus, mechanisms by which AP-1 regulates G 1 cyclins are complicated. Interaction of the AP-1 factor and the AP-1 binding site at the cyclin D1 promoter was shown here to directly contribute to the basal promoter activity of the cyclin D1 gene. An important additional finding in these studies was that the attenuation of the E2F1, E2F2 and DP1 expression by Tam67 caused a negative regulation of cyclin D1 expression through the E2F site in cyclin D1 promoter. Thus, both the basal and activated cyclin D1 transcriptional activities are Our results also demonstrate that E2F1, E2F2 and DP1 proteins are regulated by AP-1. The E2F family of transcription factors has been shown to be involved in many aspects of fundamental cell cycle control. E2F1-3 binds to cell cycle-regulated gene promoters and activate transcription of these genes. E2F1 is a proliferation 
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Q Shen et al marker of breast cells, 6.3% of cells seen in ductal carcinoma in situ were E2F1 positive, 15.3% in invasive breast cancer while only 1.9% in normal breast tissue (Zhang et al., 2000) . Also, E2F1 was expressed in 44% of node-positive breast cancers and therefore serves as a prognostic marker (Han et al., 2003) . Therefore, based upon the results of our studies, it may be possible to control breast cancer cell growth by modulating E2F factors. E2F1-3 are generally considered as activators of E2F-dependent gene expression, while E2F4 usually functions as a repressor (Dimova and Dyson, 2005) . Our results are consistent with this notion, as we have shown that E2F1 and E2F2 were significantly suppressed by Tam67-induced AP-1 blockade while E2F4 was upregulated. This is in line with the literature demonstrating that E2F4 is a functional antagonist of E2F1, 2 and 3 proteins. Interestingly, the dimerizing partner of E2F factors, DP1, but not DP2, was differentially downregulated by AP-1 blockade. This would have reduced the available level of DP1 protein and eventually the E2F/DP complexes. This also suggests a hypothesis that different dimerizing partners may preferentially form specific dimer complexes with different E2F family members. From our previous findings and the results presented herein, it is evident that AP-1 blockade by Tam67 causes global inhibition of G 1 cyclins D and E, as well as other cell cycle regulators in G 1 phase. The E2F transcription factors are key regulators of cell proliferation (Muller and Helin, 2000) . In fact, binding sites for E2F factors have been identified in a large number of genes that control cell cycle and DNA synthesis, including cdk 2 and 4, cyclin A, D and E, DNA polymerase, ribonucleotide reductase and PCNA as reviewed (Yamasaki, 1998) . It was also shown that E2F1 and E2F2 transcription factors regulate their own transcriptional activity by binding to the E2F site in the promoters of E2F1, E2F2, pRB and other cell cycle regulators (Yamasaki, 1998) . We have previously showed that AP-1 blockade reduced E2F promoter activity , and now have demonstrated that the E2F1 and E2F2 proteins were decreased, consistent with the decreased promoter activity of these genes.
The importance of the AP-1 factor in regulating breast cancer cell growth has been demonstrated by our laboratory and other investigators. Clinically, AP-1 expression is related to the estrogen receptor (ER)-negative phenotype and is a marker of poor prognosis, and AP-1 proteins are variably expressed in human breast cancer tissues (Chen et al., 1996) . cJun, the predominant AP-1 protein and the major dimerizing partner, is associated with low ER expression and tamoxifen resistance (Johnston et al., 1999; Gee et al., 2000) . Importantly, cJun regulates the growth of breast cancer cell lines. Its overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone-resistant phenotype . Taken together, these studies suggest that AP-1 plays a critical role in regulating breast cell proliferation and may have an important role in the development of breast cancers, including ER-negative breast cancer and tamoxifenresistant breast cancers.
We have previously demonstrated that Tam67 blocks the cell cycle at the G 0 /G 1 phase by reducing phosphoRb levels and downregulating cyclin D, cyclin E, CDK2/4 and p21. We have now further characterized the effect of AP-1 blockade and shown that Tam67 suppresses the cell cycle by downregulating cyclin D1 and transcription factors E2F1 and E2F2, and their dimerization partner DP1. These results suggest that targeting the AP-1 transcription factor results in cell cycle blockade, and that such targeted therapy may be useful for breast cancer treatment.
Materials and methods
Cell culture and transfection MCF-7 Tet-Off Tam67 clones #62, #67 and vector clones #1 and #3 have been described previously .
Cyclin D1 promoter constructs Cyclin D1 deletion constructs were obtained from Dr R Mü ller (Herber et al., 1994) . The D1D-848pXP2 and D1D-742pXP2 plasmids were used to mutate the E2F sites at À726/À719 (TTTCGGGC to TTTCATTC) and À139/À131 (TTTGGCGC to TTTGATTC), using a QuickChange XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). A 220 bp fragment was amplified with the primer set used in ChIP assay containing the E2F site at À726/À719 and cloned into the linearized D1D-543pXP2 plasmid, in front of Western blot analysis Western blotting was conducted as previously described . The antibodies were: cyclin D1 (sc-8396), cyclin E (sc-247), E2F2 (sc-633), E2F4 (sc-866) and DP1 (sc-610), from Santa Cruz Biotech Inc. (Santa Cruz, CA, USA) and E2F1 (#36901, Active Motif, CA, USA).
